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 Synthetic small molecular antimicrobial peptidomimetics represent a promising new class of potential 
antibiotics due to their membrane-disrupting ability and their decreased propensity for bacterial resistance. A 
library of 43 mono- and di-cationic biaryl 1,2,3-triazolyl peptidomimetics was designed and synthesized based 
upon previously established lead biarylpeptidomimetics and a known pharmacophore. A reliable, facile and 
modular synthetic pathway allowed for the efficient synthesis of multiple unique scaffolds which were subjected 
to divergent derivatization to furnish the amphiphilic compounds. In vitro testing revealed enhanced antibacterial 
efficacy against a range of pathogenic bacteria, including bacterial isolates with methicillin, vancomycin, 
daptomycin, or multi-drug resistance. Preliminary time-kill kinetics and membrane-disruption assays revealed a 
likely membrane-active mechanism for the tested peptidomimetics. An optimal balance between hydrophobicity 
and cationic charge was found to be essential for reduced cytotoxicity/haemolysis (i.e. membrane selectivity) and 
enhanced Gram-negative activity. The cationic biaryl amphiphile 81 was identified as a potent, broad-spectrum 
peptidomimetic with activity against Gram-positive (methicillin-resistant Staphylococcus aureus - MIC = 2 










The emergence and increasing prevalence of bacterial resistance to modern anthropogenic antibiotics has 
been identified as a global healthcare crisis and drug resistant bacterial infections have been categorized as an 
“emergent global disease” by the World Health Organization (WHO) and the US Centers for Disease Control and 
Prevention (CDC) [1-4]. Infectious disease is the second leading killer globally (17 million deaths annually) and 
the CDC estimates that antibacterial resistance is responsible for two million infections and 23,000 deaths in the 
USA per annum [2, 5]. Multi-drug resistant (MDR) organisms are particularly concerning and the ESKAPE 
pathogens (i.e. Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa and Enterobacter spp.) are six antibiotic resistant bacteria that have been identified by 
multiple agencies, including the Infectious Diseases Society of America (IDSA), as key pathogens behind the 
majority of nosocomial infections [6]. These bacteria have been identified due to their virulence, tenacity, 
propensity for resistance and pathogenicity [6]. There currently exists an urgent unmet need for novel antibiotic 
chemotherapeutics to combat MDR bacterial infections and the IDSA has instituted the “10 by ‘20” Initiative, 
which aims to facilitate the discovery and development of 10 novel antibiotics drugs by the year 2020 [3, 5, 7].  
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Antimicrobial peptides (AMPs) are found in a wide array of organisms where they provide a natural defence 
against invading microbial pathogens [8]. These peptides are typically cationic and amphiphilic in nature because 
they contain basic amino acids (cationic at physiological pH) and a high percentage (>50%) of hydrophobic side 
chain residues [9-10]. The cationic residues allow for electrostatic attraction to the anionic bacterial membrane 
while the hydrophobic residues insert into the lipophilic interior of the lipid bilayer membrane; this ultimately 
results in disruption of the membrane integrity and can lead to cell death [8-10]. AMPs are generally thought to 
exhibit a reduced propensity for bacterial resistance due to their unique mode of action (i.e. cellular membrane 
disruption) [9]; despite this, acquired resistance to AMPs and small molecular peptidomimetics has been 
documented [10-11]. Unfortunately, most naturally occurring AMPs have limited applicability due to their in vivo 
toxicity (i.e. lack of membrane selectivity), high manufacturing costs and their susceptibility to protease 
metabolism [9, 12-13]. Recent developments in small molecular AMP mimics aim to eliminate these limitations 
[12-21]. One successful example is LTX-109, a three-residue AMP mimic by Lytix Biopharma that has completed 
Phase 2 clinical trials as a topical agent for nasal decolonization of MRSA [22-23].  
Most AMP mimics are non-selective towards cellular membranes and thus exhibit haemolytic and cytotoxic 
activity against mammalian cells. Small molecular AMP mimics often display a positive correlation between 
antibacterial activity and cytotoxicity due to their non-selective membrane disrupting ability, which precludes 
these molecules from becoming effective systemic antimicrobial drugs [24]. Fine-tuning the membrane selectivity 
to target bacterial membranes over eukaryotic membranes will be essential for the development of an effective 
membrane-disrupting, systemically administered antibiotic. Liu and co-workers [16] have successfully explored 
the hydrophobic/cationic balance in xanthone derivatives, developing compounds that exhibit virtually no 
haemolysis while maintaining potent antibacterial activity against Gram-positive bacteria. Antibacterial efficacy 
against Gram-negative bacteria is ultimately needed, as many of the resistant pathogenic bacteria, such as the 
ESKAPE pathogens, are Gram-negative (e.g. K. pneumoniae, A. baumannii and P. aeruginosa) [6, 25].  
Previous work in our laboratory has produced a promising class of biaryl cationic peptidomimetics that exhibit 
antimicrobial activity against a broad range of Gram-positive and Gram-negative pathogenic bacteria, including 
the problematic Clostridium difficile and bacterial strains that are resistant to methicillin, vancomycin and 
linezolid [14-15, 26-29]. The systemic and topical antibacterial efficacy of these compounds has been 
demonstrated in vivo with methicillin-resistant S. aureus (MRSA) infection models in mice [26]. Recent studies 
have led to the development of peptidomimetic compound 1, which incorporates a 1,2,3-triazole moiety as a 
protease-resistant peptide bioisostere; this derivative was also shown to exhibit potent minimum inhibitory 
concentration (MIC) values against Gram-positive and Gram-negative bacteria (Fig. 1) [14]. The biaryl cationic 
peptidomimetics conform to a simple, preliminary pharmacophore model [14] that comprises a biaryl aromatic 
core with attached cationic residues and hydrophobic residues; this confers an amphiphilic structure to the 
compounds which is essential for antibacterial efficacy. This pharmacophore is analogous to other AMP mimic 
models, such as those proposed by Haldar et al. [12] and Kumar et al. [13]; further elucidation of the essential 
components for broad-spectrum antibacterial efficacy and membrane selectivity will allow for the rational design 
of potent and selective AMP mimics for potential use as chemotherapeutic agents.  
 
Fig. 1. Lead peptidomimetic compound 1. 
In this current study, lead compound 1 was structurally modified to obtain novel AMP mimics with increased 
solubility and antibacterial efficacy against Gram-negative bacteria. Modification strategies included further 
incorporation of peptidomimetic 1,2,3-triazole moieties for enhanced metabolic stability, replacement of the 
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binaphthalene aromatic core with the more soluble biphenyl moiety and manipulation of the cationic/hydrophobic 
residue arrangements. These modifications allowed for the synthesis of 43 novel biaryl cationic peptidomimetics 
with significant antibacterial activity against various pathogenic Gram-positive and Gram-negative bacteria. 
Additionally, selected derivatives were subjected to time-kill kinetics and membrane disruption assays to 
investigate the antibacterial mode of action. Haemolysis and in vitro cytotoxicity assays were utilized to identify 
any eukaryotic cytotoxicity.  
 
2. Results and Discussion 
2.1. Design, synthesis and characterization of cationic biaryl peptidomimetic amphiphiles 
Three distinct classes of cationic biaryl 1,2,3-triazolyl amphiphiles were designed and synthesized for 
antibacterial evaluation: monocationic terminal amide analogues (A), dicationic terminal amide analogues (B) 
and dicationic bis-triazole derivatives (C) (Fig. 2). 
 
 
Fig. 2. General structures of the cationic biaryl 1,2,3-triazolyl peptidomimetic amphiphiles (Series A, B and C) 
synthesized in this study. 
Previous investigations established the efficacy of 1,2,3-triazole moieties as bioisosteric amide bond replacements 
in the biaryl cationic amphiphiles (e.g. lead compound 1) [14]. Therefore, the biaryl amide linker in lead 
compound 1 was targeted for bioisosteric triazole substitution; subsequent variation of the biaryl core (i.e. (S)-
binaphthyl or biphenyl), cationic amino acid residues (i.e. Lys and/or Arg) and the hydrophobic termini linker 
(i.e. amide or 1,2,3-triazole) led to the development of Series A, B and C peptidomimetics. The unnatural D-
configured amino acids were utilized as they have been shown to confer increased metabolic stability to AMPs 
[30]. 
A modular synthetic approach was employed for the construction of multiple unique peptidomimetic scaffolds 
from key azide, alkyne, acid and amine building blocks. Cu-catalysed azide-alkyne cycloaddition (CuAAC) and 
peptide coupling reactions were exploited to assemble the various scaffolds, as exemplified in Scheme 1. The 
terminal amine or azide scaffolds (e.g. compound 7 or 10) served as divergence points from which multiple 
antimicrobial derivatives were realized. The hydrophobic termini were installed via peptide coupling or CuAAC 
reaction; subsequent acidolytic deprotection of the cationic side-chains furnished the final compounds as mono- 




Scheme 1. Modular synthetic strategy utilized to achieve Series A and Series C derivatives. 
The biphenyl (15) and (S)-binaphthyl (16) alkyne building blocks were obtained in excellent yield via sequential 
O-alkylation [27-28, 31] and O-propargylation reactions of the commercially available 2,2ʹ-biphenol (11) or 2,2ʹ-
binaphthol (12) starting materials (Scheme 2).  
 
Scheme 2. Synthesis of precursor alkynes 15 and 16. 
The required azido amine precursors were constructed from commercially available D-amino acids. Mixed 
anhydride reduction of the N-Cbz amino acids (17 and 18) furnished the corresponding alcohols (19 and 20) which 
were then subjected to a two-step, one-pot mesylation/azidation reaction sequence to yield the N-Cbz azido amine 
building blocks 21 and 22 (Scheme 3). Azido acids 25 and 26 were synthesized via diazotransfer reaction of the 
corresponding D-amino acids (Scheme 4a) and the N-Boc azido amine 28 was realized by reaction of the known 




Scheme 3. Synthesis of N-Cbz azido amines 21 and 22. 
 
 
Scheme 4. Azide precursors: a) Synthesis of azido acids 25 and 26. b) Synthesis of N-
Boc-β-azido-amine 28. 
The N-protected Series A scaffold intermediates (29–33) were constructed by CuAAC reactions between the 
corresponding aromatic alkyne (15 or 16) and azide (21, 22 or 28) precursor building blocks (Scheme 5). The 
sterically hindered (S)-binaphthyl analogues 31–33 required an increased reaction temperature (45 °C) to furnish 
the desired 1,2,3-triazole products. The 1,4-regioselectivity of the CuAAC reaction [32-34] was elucidated by 
analysis of the gHMBC NMR spectrum of the resultant N-deprotected scaffold amine 34 (Fig. S23). 
 
 
Scheme 5. Synthesis of the Series A scaffold intermediates. 
6 
 
Terminal group deprotection of the N-Cbz intermediates 29–31 by catalytic hydrogenolysis over Pd/C and H2 gas 
gave access to scaffold amines 34–36, while the N-Boc scaffold 33 was subjected to mild acidolytic conditions 
via anhydrous HCl in MeOH/Et2O to achieve scaffold amine 37 without removal of the more robust N-Pbf moiety 
(Scheme 6). 
 
Scheme 6. Synthesis of Series A amine scaffolds via terminal N-deprotection. Reagents and conditions: A) 10% Pd-C 
(0.15 eq), H2 (1 atm), AcOH (20.0 eq), MeOH, rt, 24 h; B) HCl (20.0 eq), MeOH, rt, 18 h. 
 
Derivatization of the Series A scaffold amines (34–37) was accomplished by EDCI/HOBt promoted amide bond 
formation with various hydrophobic carboxylic acids (R-COOH) in CH3CN; acidolytic N-deprotection of the 
cationic side-chains with TFA/CH2Cl2/H2O followed by treatment with HCl/Et2O yielded the Series A 
monocationic amphiphiles 38–63 (Table 1) as their hydrochloride salts. 
 
Table 1. Synthesis of the Series A monocationic amphiphiles. 
 
Entry Compound Aromatic Core AA·HCl R Yield(%)a 
1 38 Biphenyl Lys 
 
96 
2 39 Biphenyl Lys 
 
93 
3 40 Biphenyl Lys 
 
93b 
4 41 Biphenyl Arg 
 
84 
5 42 Biphenyl Arg 
 
95 
6 43 Biphenyl Arg 
 
87b 
7 44 (S)-Binaphthyl Lys 
 
95 
8 45 (S)-Binaphthyl Lys 
 
82 
9 46 (S)-Binaphthyl Lys 
 
99b 





11 48 (S)-Binaphthyl Lys 
 
82 
12 49 (S)-Binaphthyl Lys 
 
85 
13 50 (S)-Binaphthyl Lys 
 
67 
14 51 (S)-Binaphthyl Lys 
 
90 
15 52 (S)-Binaphthyl Lys 
 
77 
16 53 (S)-Binaphthyl Lys 
 
67 
17 54 (S)-Binaphthyl Lys 
 
73 
18 55 (S)-Binaphthyl Lys 
 
88 
19 56 (S)-Binaphthyl Lys 
 
86 
20 57 (S)-Binaphthyl Lys 
 
74 
21 58 (S)-Binaphthyl Lys 
 
86 
22 59 (S)-Binaphthyl Lys 
 
85 
23 60 (S)-Binaphthyl Lys 
 
88 
24 61 (S)-Binaphthyl Arg 
 
86 
25 62 (S)-Binaphthyl Arg 
 
89 
26 63 (S)-Binaphthyl Arg 
 
96b 
a Yields are reported over two steps. 
b Synthesised in one step from the corresponding N-Cbz protected scaffold intermediate. 
 
Series B scaffold amines 64 and 65 were synthesized from scaffold amine 34 or 36 by EDCI/HOBt peptide 
coupling with Fmoc-(D)-Arg(Pbf)-OH followed by base-promoted N-Fmoc deprotection (Scheme 7). 
Derivatization of the Series B scaffold amines was accomplished by the general peptide coupling/side-chain 
deprotection sequence, thus furnishing the Series B dicationic amphiphiles 68–74 (Table 2) as their di-
hydrochloride salts. 
The Series C scaffold azides 75–77 were assembled from scaffold amines 34–36 by EDCI/HOBt peptide coupling 
with the corresponding azido acid precursor (25 or 26) (Scheme 8). The resultant azides were then subjected to 
derivatization via sequential CuAAC reaction and acidolytic side-chain deprotection to achieve the Series C 
dicationic amphiphiles 78–87 (Table 3) as their di-hydrochloride salts. 
The employed synthetic methodology was amenable to scale-up; compounds 80 and 81 were prepared in >1 gram 
quantities (for in vivo assays) and their purity was confirmed (>97%) by reverse-phase analytical HPLC (Fig. S28 
and S29). 
Notably, some of the synthesized amphiphilic peptidomimetics (e.g. compounds 40 and 81) failed to display 13C 
NMR resonances that could be assigned to the quaternary triazole carbons when the spectra were acquired in 
CDCl3 or CD3OD; for instance, compound 81 required gHMBC correlations with the adjacent triazole methine 
protons to allow for assignment of both quaternary triazole carbons (Fig. S24). gHMBC analysis did not show the 
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relevant correlations for compound 40 when the spectrum was acquired in CD3OD; the 13C DEPT Q NMR 
spectrum had to be acquired in DMSO-d6 for the requisite carbon resonance to be clearly visible. 
The presence of carbamate and amide rotamers was observed in the 1H and 13C NMR spectra of particular 
derivatives. Compound 40 was found to exhibit rotameric shouldering in the 1H NMR spectrum (Fig. S25) and 
similar rotameric “shoulder” resonances in the 13C NMR spectrum (Fig. S26). The presence of syn- and anti-
rotamers was confirmed by variable temperature NMR experiments; the observed resonance splitting in the 13C 
NMR spectrum of compound 40 was reduced when the spectrum was acquired in DMSO-d6 and the splitting was 
completely eliminated when the 13C NMR spectrum was acquired in DMSO-d6 at 90 °C (Fig. S27). 
 
Scheme 7. Synthesis of the Series B amine scaffolds 64 and 65. Reagents and conditions: A) Piperidine (5.0 eq), CH3CN, rt, 
18 h; B) tris-(2-aminoethyl)amine (5.0 eq), CH3CN, rt, 18 h. a By-products from N-Fmoc deprotection reaction.  
 
Table 2. Synthesis of the Series B dicationic amphiphiles. 
 
Entry Compound Aromatic Core R Yield(%)a 
1 68 Biphenyl 
 
61%b 
2 69 Biphenyl 
 
95%c 
3 70 (S)-Binaphthyl 
 
73% 
4 71 (S)-Binaphthyl 
 
77% 
5 72 (S)-Binaphthyl 
 
79% 





7 74 (S)-Binaphthyl 
 
85%c 
a Yields are reported over two steps. 
b Yield is reported over four steps from scaffold amine 34. 







Scheme 8. Synthesis of the Series C azide scaffolds 75–77. 
 
 
Table 3. Synthesis of the Series C dicationic amphiphiles. 
 
 
Entry Compound Aromatic Core AA1·HCl AA2·HCl R Yield(%)
a 
1 78 Biphenyl Lys Arg 
 
86 
2 79 Biphenyl Lys Arg 
 
94 
3 80 Biphenyl Lys Arg 
 
92 
4 81 Biphenyl Lys Arg 
 
79 
5 82 Biphenyl Arg Lys 
 
97 
6 83 Biphenyl Arg Lys 
 
95 





8 85 Biphenyl Arg Lys N/Ab 97 
9 86 (S)-Binaphthyl Lys Arg 
 
58 
10 87 (S)-Binaphthyl Lys Arg 
 
74 
a Yields are reported over two steps. 
b No terminal triazole moiety; synthesised by N-deprotection of the corresponding azide scaffold. 
 
2.2. Antibacterial activity evaluation 
 The Series A, B and C peptidomimetic amphiphiles were screened in an in vitro MIC assay against a 
primary panel of Gram-positive pathogenic bacteria; vancomycin was used a positive control and the results are 
displayed in Tables 4, 5 and 6. Selected compounds were then tested against a secondary panel of pathogenic 
Gram-negative bacteria and MRSA at the Community for Open Antimicrobial Drug Discovery (CO-ADD) [35]. 
CO-ADD also performed a cytotoxicity concentration (CC50) assay against the selected compounds at 
concentrations ≤32 µg/mL. Vancomycin, colistin and tamoxifen were used as positive controls in the Gram-
positive, Gram-negative and cytotoxicity assays, respectively. The resultant CO-ADD antibacterial activities and 
CC50 values from Series A, B and C are displayed in Tables 7, 8 and 9, respectively. Additionally, four compounds 
(41, 45, 71 and 73) were tested against an extended panel of drug-resistant Gram-positive pathogens at CO-ADD 
with vancomycin and daptomycin as positive controls; the results are displayed in Table 10.   
2.2.1. Series A derivatives 
Primary screening results for the monocationic Series A derivatives (Table 4) indicated successful bioisosteric 
substitution of the biaryl amide linker with the 1,4-disubstituted-1,2,3-triazole moiety; the synthesized (S)-
binaphthyl monocationic derivatives (44–63) exhibited significant antibacterial efficacy and most compounds 
displayed MIC values ranging from 4–8 µg/mL against S. aureus. The incorporation of bulky (e.g. naphthyl, 
compound 51) and hydrophilic (e.g. 4-amino-tetrahydropyran-4-yl, compound 60) terminal substituents led to a 
decrease in antibacterial efficacy against Gram-positive bacteria; compounds 51 and 60 exhibited less potent MIC 
values of 16 µg/mL against S. aureus (Table 4). (S)-binaphthyl derivatives 44–63 also exhibited antibacterial 
activity against E. faecalis (MIC = 8–16 µg/mL) with reduced antibacterial efficacy against Staphylococcus 
pneumoniae (MIC = 8–32 µg/mL) and C. difficile (MIC = 16–64 µg/mL). The (S)-binaphthyl monocationic 
arginine analogues 61–63 were notably more potent than their lysine counterparts (44–46), as they were the only 
monocationic (S)-binaphthyl analogues to exhibit strong antibacterial efficacy against S. pneumoniae (MIC = 8 
µg/mL). 
Replacement of the (S)-binaphthyl aromatic core with a biphenyl core did not adversely affect the antimicrobial 
efficacy of the monocationic amphiphiles. While a slight reduction in potency was observed for some analogues 
and Gram-positive strains (e.g. biphenyl compound 41 exhibits MIC values against S. aureus that are 4× less 
potent than its (S)-binaphthyl analogue 61), an increase in potency was noted for other strains (e.g. biphenyl 
compound 41 exhibits MIC values against C. difficile PCR ribotype (RT) 027 that are 4× more potent than its (S)-
binaphthyl analogue 61) – see Table 4. The overall effect of aromatic core replacement on the antibacterial 
efficacy of the cationic amphiphiles was highly species dependent. Most notably, the biphenyl compounds 39 and 
40 exhibited increased potency against C. difficile (MIC = 8 µg/mL) relative to their (S)-binaphthyl analogues 45 
and 46 (MIC = 32 µg/mL). Furthermore, biphenyl derivatives 38 and 39 exhibited a 2–4× fold increase in activity 
against S. pneumoniae when compared to their (S)-binaphthyl analogues 44 and 45. Secondary screening of 
selected Series A monocationic derivatives against Gram-negative pathogens and MRSA at CO-ADD further 
confirmed that replacement of the (S)-binaphthyl core with a biphenyl aromatic core resulted in a reduction of 
antibacterial potency against MRSA (Table 7). The selected monocationic derivatives were generally not active 
at the concentrations tested or only mildly active (MIC = 32 µg/mL) against the pathogenic Gram-negative 
bacteria (Table 7). Ultimately, compounds 39 and 62 were identified as the most promising derivatives from Series 
A, with MIC values ranging from 4–16 µg/mL for all tested Gram-positive bacterial strains.  
2.2.2. Series B derivatives 
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The addition of a second cationic residue to give Series B dicationic terminal amides (68–74) led to a general 
increase in antibacterial efficacy; e.g. (S)-binaphthyl dicationic compounds 70 and 71 exhibited MIC values of 2 
µg/mL against MRSA (Table 8). Notably, the antibacterial activity against all Gram-positive bacteria was 
increased for the Series B dicationic amides relative the Series A monocationic derivatives; MIC values as low as 
2 µg/mL against E. faecalis, 4 µg/mL against S. pneumoniae and 8 µg/mL against C. difficile (ATCC 70057) were 
observed (Table 5). The Series B dicationic biphenyl analogues (68 and 69) exhibited similar antibacterial 
activities relative to the (S)-binaphthyl analogues 70–74; biphenyl compound 68 was found to be approximately 
2× less potent than its (S)-binaphthyl analogue 70, whereas biphenyl compound 69 was found to be 2× more 
potent than its (S)-binaphthyl analogue 74 (Table 5). Most notably, the addition of a second cationic amino acid 
residue conferred antimicrobial activity against Gram-negative bacteria to the Series B dicationic derivatives; 
compounds 70 and 71 exhibited MIC values ranging from 8–16 µg/mL against both E. coli and P. aeruginosa 
(Table 8). The general increase in antimicrobial activity seen with the addition of a second cationic residue is 
likely a result of the increased electrostatic interactions between the cationic molecule and the anionic bacterial 
membrane. Furthermore, an increase in the number of cationic residues relative to the hydrophobic substituents 
may confer a more optimized amphiphilic structure to the compounds. Compound 72 was found to exhibit the 
best MIC profile against Gram-positive bacteria amongst the Series B analogues.    
2.2.3. Series C derivatives 
The incorporation of a second bioisosteric 1,2,3-triazole moiety to give the Series C biphenyl dicationic terminal 
triazoles 78–85 resulted in a substantial increase in antibacterial efficacy against Gram-negative bacteria (Table 
9). Compound 79 exhibited MIC values of 4–16 µg/mL against P. aeruginosa, K. pneumoniae, A. baumannii and 
E.coli (Table 9). The resultant increase in Gram-negative activity for the biphenyl bis-triazoles 78–85 was less 
easily explained, given that the same terminal bioisosteric 1,2,3-triazole substitution did not confer an increase in 
Gram-negative activity to the (S)-binaphthyl analogues 86 and 87; these analogues exhibited similar Gram-
negative MIC values relative to the Series B terminal amide analogues 70 and 71 (Tables 8 and 9).  The balance 
of hydrophobicity and cationicity proved essential for effective antibacterial Gram-negative activity in compounds 
78–85; increasing the hydrophobicity (replacement of biphenyl with an (S)-binaphthyl, e.g. compounds 86 or 87 
– Table 9) or decreasing the cationicity (e.g. Series A monocationic derivatives – Table 7) resulted in a loss of 
efficacy against Gram-negative bacteria. Compound 81 was identified as a potent derivative with broad spectrum 
activity, exhibiting MIC values of 2–4 µg/mL against all tested Gram-positive bacteria and 4–16 µg/mL against 
all tested Gram-negative bacteria. 
2.2.4. Hydrophobic terminus variation 
The presence of a terminal hydrophobic residue was essential for potent antimicrobial activity; compound 85, 
which comprised a bare azide terminus rather than a 1,2,3-triazole linked hydrophobic residue, was found to  
exhibit MIC values that were 2–4× less potent than its related derivatives 82–84. The essential nature of the 
hydrophobic terminus was also observed amongst the Series A monocationic derivatives, as hydrophilic termini 
(e.g. compounds 59 and 60) resulted in decreased antibacterial efficacy (Table 4).  For the Gram-positive bacteria, 
the more flexible, hydrophobic termini were found to be slightly more potent: e.g. compound 79 (phenethyl 
terminus) was slightly more potent than compound 78 (benzyl terminus) and compound 81 (cyclohexylmethyl 
terminus) was slightly more potent against some Gram-positive bacteria than compound 80 (cyclohexyl terminus) 
– see Table 6. This pattern was not observed amongst the Gram-negative bacterial species and no correlation 
between termini type and antibacterial activity could be drawn for the Gram-negative bacteria (Table 9). 
2.2.4. Amino acid orientation 
The orientation of the cationic residues was found to impact the antibacterial efficacy against specific strains. 
Reversing the Lys-Arg orientation (e.g. compounds 78–81) to Arg-Lys (e.g. compounds 82–84) did not drastically 
affect the MIC values against most bacterial species, although a substantial difference in antibacterial efficacy 
was observed for C. difficile and K. pneumoniae; the Lys-Arg orientation was found to be superior in both cases 
(Tables 6 and 9, respectively). 
2.2.5. MIC testing against an extended panel of drug-resistant Gram-positive bacteria 
Notably, MIC testing of compounds 45, 49, 71 and 73 against an extended panel of Gram-positive bacteria  
showed that the cationic amphiphiles exhibit potent antimicrobial activity against a broad range of drug-resistant, 
Gram-positive pathogens (Table 10), including MRSA, vancomycin-resistant S. aureus (VRSA), vancomycin-
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resistant  E. faecalis (VRE), MDR S. pneumoniae and S. aureus with reduced susceptibility to daptomycin. Potent 
MIC values of 1–4 µg/mL were observed for the dicationic amphiphiles 71 and 73 against every drug resistant 
Gram-positive bacteria tested. Antibacterial activity against these resistant isolates provides further evidence for 
a distinct mechanism of action relative to vancomycin, daptomycin and methicillin.  
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1 38 Biphenyl Lys Bn 8 8 8 8 32 32 
2 39 Biphenyl Lys PhEt 8 4 8 8 8 16 
3 40 Biphenyl Lys OBn 16 16 16 32 8 32 
4 41 Biphenyl Arg Bn 16 16 16 16 64 16 
5 42 Biphenyl Arg PhEt 16 16 16 32 128 16 
6 43 Biphenyl Arg OBn 4 4 8 16 32 32 
7 44 (S)-Binaphthyl Lys Bn 8 8 8 32 16 32 
8 45 (S)-Binaphthyl Lys PhEt 4 8 8 16 32 32 
9 46 (S)-Binaphthyl Lys OBn 4 8 8 16 32 32 
10 47 (S)-Binaphthyl Lys Ph 8 8 8 16 32 32 
11 48 (S)-Binaphthyl Lys Phenylpropyl 8 16 8 32 32 64 
12 49 (S)-Binaphthyl Lys Piperonyl 8 8 8 16 32 32 
13 50 (S)-Binaphthyl Lys 4-CH3-Bn 8 8 8 32 16 32 
14 51 (S)-Binaphthyl Lys Naphth-2-yl 16 16 8 32 64 64 
15 52 (S)-Binaphthyl Lys 4-Br-Bn 4 8 8 32 32 64 
16 53 (S)-Binaphthyl Lys Furan-2-yl 8 8 8 16 16 32 
17 54 (S)-Binaphthyl Lys Thiophen-2-yl 8 8 8 16 32 64 
18 55 (S)-Binaphthyl Lys Cyclopentenyl 8 8 8 16 32 64 
19 56 (S)-Binaphthyl Lys Cyclopropyl 8 8 8 16 16 64 
20 57 (S)-Binaphthyl Lys Cyclohexenyl 8 8 8 16 32 32 
21 58 (S)-Binaphthyl Lys Isobutyl 8 8 8 16 16 32 
22 59 (S)-Binaphthyl Lys 2-Pyrrolid-one-5-yl 16 16 16 32 32 64 
23 60 (S)-Binaphthyl Lys 4-NH2-tetrahydropyran-4-yl 16 16 16 16 32 64 
24 61 (S)-Binaphthyl Arg Bn 4 4 8 8 64 64 
25 62 (S)-Binaphthyl Arg PhEt 4 4 8 8 16 16 
26 63 (S)-Binaphthyl Arg OBn 4 4 8 8 32 32 
27 Vancomycin - - - 1 1 4 1 0.5 0.5 
14 
 
Table 5. Primary screening: antibacterial activities of Series B derivatives reported as MIC values (μg/mL). 
 
 






























1 68 Biphenyl Bn 8 8 8 8 16 16 
2 69 Biphenyl Fmoa 4 4 4 4 32 32 
3 70 (S)-Binaphthyl Bn 2 4 4 4 8 16 
4 71 (S)-Binaphthyl PhEt 4 4 4 4 16 32 
5 72 (S)-Binaphthyl Phenylpropyl 2 4 2 4 8 16 
6 73 (S)-Binaphthyl Piperonyl 4 4 4 4 8 32 
7 74 (S)-Binaphthyl Fmoa 8 8 8 8 32 64 
8 Vancomycin - - 1 1 4 1 0.5 0.5 
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a No terminal triazole moiety; synthesised by N-deprotection of the corresponding azide scaffold. 
 

















1 78 Biphenyl Lys Arg Bn 8 8 16 4 16 16 
2 79 Biphenyl Lys Arg PhEt 4 4 8 8 8 8 
3 80 Biphenyl Lys Arg Cy 8 4 8 4 4 8 
4 81 Biphenyl Lys Arg CH2Cy 4 4 4 4 4 4 
5 82 Biphenyl Arg Lys Bn 4 4 8 4 64 64 
6 83 Biphenyl Arg Lys PhEt 4 4 8 4 16 16 
7 84 Biphenyl Arg Lys Cy 4 4 8 4 32 32 
8 85 Biphenyl Arg Lys N/Aa 16 16 16 8 64 32 
9 86 (S)-Binaphthyl Lys Arg PhEt 4 4 4 4 16 16 
10 87 (S)-Binaphthyl Lys Arg CH2Cy 4 4 4 4 8 16 











































1 38 Biphenyl Lys Bn 16 32 >32 32 >32 14.2 
2 39 Biphenyl Lys PhEt 16 32 32 >32 32 4.8 
3 40 Biphenyl Lys OBn 16 32 >32 32 32 4.7 
4 41 Biphenyl Arg Bn 16 >32 >32 >32 >32 29.0 
5 42 Biphenyl Arg PhEt 16 >32 >32 >32 >32 >32 
6 43 Biphenyl Arg OBn 8 >32 >32 >32 >32 >32 
7 44 (S)-Binaphthyl Lys Bn 8 >32 >32 >32 >32 8.6 
8 45 (S)-Binaphthyl Lys OBn 4 >32 >32 >32 >32 3.5 
9 61 (S)-Binaphthyl Arg Bn 4 >32 >32 >32 >32 16.5 
10 62 (S)-Binaphthyl Arg PhEt 4 >32 >32 >32 >32 15.9 
11 63 (S)-Binaphthyl Arg OBn 4 >32 >32 >32 >32 13.8 
12 Vancomycin - - - 1 - - - - - 
13 Colistin - - - - 0.25 0.25 0.25 0.125 - 
14 Tamoxifen - - - - - - - - 13.1 
 
 




























1 68 Biphenyl Bn 4 32 32 32 16 32 
2 69 Biphenyl Fmo 4 >32 >32 >32 >32 >32 
3 70 (S)-Binaphthyl Bn 2 16 32 32 8 12.1 
4 71 (S)-Binaphthyl PhEt 2 16 32 32 8 27.4 
5 Vancomycin - - 1 - - - - - 
6 Colistin - - - 0.25 0.25 0.25 0.125 - 




Table 9. Secondary screening: antibacterial activities of selected Series C derivatives, reported as MIC values (μg/mL). 
a No terminal triazole moiety; synthesised by N-deprotection of the corresponding azide scaffold. 
 
Table 10. Extended Gram-positive screening panel: antibacterial activities of selected derivatives, reported as MIC values (μg/mL). 
a Glycopeptide intermediate susceptibility S. aureus (GISA) 
b MRSA/reduced daptomycin susceptibility 
c Vancomycin resistant S. aureus (VRSA) 

































1 78 Biphenyl Lys Arg Bn 4 16 16 8 16 21.9 
2 79 Biphenyl Lys Arg PhEt 2 8 16 16 8 >32 
3 80 Biphenyl Lys Arg Cy 4 8 16 16 8 14.2 
4 81 Biphenyl Lys Arg CH2Cy 2 16 16 8 4 >32 
5 82 Biphenyl Arg Lys Bn 4 16 32 16 8 17.8 
6 83 Biphenyl Arg Lys PhEt 2 8 16 16 4 17.4 
7 84 Biphenyl Arg Lys Cy 4 8 32 8 8 15.3 
8 85 Biphenyl Arg Lys N/Aa 8 32 32 16 16 >32 
9 86 (S)-Binaphthyl Lys Arg PhEt 4 32 >32 32 >32 >32 
10 87 (S)-Binaphthyl Lys Arg CH2Cy 2 32 >32 16 32 >32 
11 Vancomycin - - - - 1 - - - - - 
12 Colistin - - - - - 0.25 0.25 0.25 0.125 - 
13 Tamoxifen - - - - - - - - - 13.1 
 






























1 45 OBn 2-4 16 8 8-16 8 8 8 4 
2 49 Piperonyl 8 >32 16 8-16 8 8-16 8-16 4 
3 71 PhEt 1-2 4 2 2-4 2-4 2 1-2 2 
4 73 Piperonyl 2 4 4 2-4 4 4 2 2 
5 Vancomycin - 1 2 8 8 2 2 1-2 >32 




2.3. Haemolysis Assay 
To determine the membrane selectivity of the biaryl cationic peptidomimetics, selected derivatives were 
subjected to a haemolysis assay with sheep erythrocytes at concentrations of 5 µg/mL and 50 µg/mL; UltraPure 
H2O was utilized as a positive control (i.e. 100% haemolysis) and the results are displayed in Table 11. 
 
Table 11. Percent haemolysis assay for selected derivatives from Series A, B and C. 
Entry Compound 
Testing Concentration 
5 µg/mL 50 µg/mL 
1 39 0.2% 100.8% 
2 43 0.7% 89.1% 
3 61 1.0% 87.4% 
4 68 0.6% 17.5% 
5 71 1.1% 94.2% 
6 80 1.9% 22.9% 
7 81 1.5% 42.4% 
8 83 1.7% 28.8% 
9 87 1.6% 88.8% 
 
All compounds tested exhibited minimal haemolysis at the lower testing concentration of 5 µg/mL. The Series A 
monocationic derivatives 39, 43 and 61 displayed strong haemolysis at the higher concentration of 50 µg/mL; 
these compounds displayed minimal membrane selectivity, effectively disrupting mammalian membranes at 
higher concentrations. The biphenyl dicationics 68, 80, 81 and 83 all exhibited <50% haemolysis at 50 µg/mL, 
while the (S)-binaphthyl dicationic analogues 71 and 87 displayed 94.2% and 88.8% haemolysis, respectively, at 
this higher testing concentration. The biphenyl dicationic derivatives exhibited lower haemolysis; their optimized 
cationic/hydrophobic ratio conferred increased membrane selectivity and therefore, reduced haemolysis. The 
increased hydrophobicity of the (S)-binaphthyl dicationic analogues 71 and 87 resulted in increased haemolysis, 
due to a decrease in the cationic/hydrophobic ratio relative to compounds 68, 80, 81 and 83. This correlation 
between the cationic/hydrophobic ratio and membrane selectivity will benefit the rational design of future 
amphiphilic AMP mimics.  
 
 
2.4. Time kill kinetics assay 
Compound 71 was selected for an in vitro time-kill assay against S. aureus (ATCC 29213) and E. coli 
(ATCC 25922) to ascertain the bactericidal kinetics of the cationic amphiphilic peptidomimetics synthesized in 
this study. A testing concentration of 64 µg/mL (16 × MIC for S. aureus and 8 × MIC for E. coli) was utilized and 
the results indicated that compound 71 killed S. aureus in ≤30 min and E. coli in ≤120 min (i.e. a ≥3-log10 reduction 
in bacteria - see Fig. 3). After 6 h, vancomycin displayed only a minimal reduction in S. aureus viability (Fig. 3, 
top), suggesting a distinct mode of action relative to the fast-acting cationic amphiphiles (e.g. compound 71). 
After 2 h, colistin reduced the E. coli loading below the limit of detection (Fig. 3, bottom), similar to compound 
71. Colistin is known to cause membrane-disruption of Gram-negative bacteria [9]; the comparable fast-acting 




Fig. 3. Time kill assays for compound 71 at 64 µg/mL against S. aureus (top) and E. coli (bottom). Limit of detection = 103 
CFU/mL. Vancomycin tested at 8 µg/mL (8 × MIC) and colistin tested at 4 µg/mL (32 × MIC). 
2.5. Cytoplasmic membrane depolarization assay 
A cytoplasmic membrane depolarization assay with 3,3ʹ-dipropylthiadicarbocyanine (diSC3(5)) 
fluorescent dye [13, 17] was performed on compounds 39, 71 and 81 against S. aureus and E. coli to investigate 
the mode of action for these cationic amphiphilic peptidomimetics. The electrochemical membrane potential 
forces the cationic diSC3(5) dye to sequester into the bilayer lipid membrane of the bacteria, thereby quenching 
its own fluorescence; when the cytoplasmic membrane potential is disrupted by the antimicrobial compounds, the 
diSC3(5) dye leaks out and causes an observable increase in fluorescence.     
Compounds 39, 71 and 81 were found to strongly disrupt the membrane potential of S. aureus (ATCC 29213) and 
E. coli (NCTC 10418)  when tested at 32 and 64 µg/mL, respectively (i.e. 4–32 × MIC). For S. aureus,  the 
fluorescence intensity increased by approximately 120–180% after exposure to the peptidomimetic compounds 
(Fig. 4, top). DMSO (20% aq.) was utilized as positive control and it resulted in a 90% increase in the observed 
fluorescence. Vancomycin and UltraPure H2O were utilized as negative controls; as expected, both controls failed 
to generate any increase in fluorescence, further confirming the lack of membrane disruption for vancomycin. In 
the assay against E. coli,  the fluorescence intensity increased by approximately 460–900% after exposure to the 
peptidomimetics (Fig. 4, bottom). DMSO (20% aq. – positive control) also exhibited a 900% increase in observed 
fluorescence against E. coli, whereas colistin (positive control for E. coli) displayed an approximate 400% increase 
in the observed fluorescence. The bis-triazole compound 81 exhibited the lowest MIC values (i.e. 2 µg/mL for 
MRSA and 4 µg/mL for E. coli) out of the three compounds subjected to cytoplasmic membrane depolarization 
assay and it was also found to exhibit the highest fluorescence in the assay against both S. aureus and E. coli. 
These results indicate a positive correlation between membrane depolarization activity and antibacterial efficacy, 


















































Fig. 4. Cytoplasmic membrane depolarization assays for compounds 39, 71 and 81 tested at 32 µg/mL against S. aureus (top) 
and 64 µg/mL against E. coli (bottom). Vancomycin tested at 8 µg/mL and colistin tested at 64 µg/mL. 
2.6. Cytoplasmic membrane permeabilization assay 
A cytoplasmic membrane permeabilization assay with propidium iodide [17-18] was performed on 
compounds 39, 71 and 81 against S. aureus (ATCC 29213) and E. coli (NCTC 10418) to confirm their membrane-
disrupting ability. The propidium iodide dye does not permeate the cellular membrane of the bacteria unless the 
membrane has been disturbed; if large enough pores are formed, the dye can enter the cytoplasm and stain the 
DNA, which results in fluorescence.  
The tested compounds (39, 71 and 81) were found to effectively permeabilize the cytoplasmic membrane of S. 
aureus (Fig. 5, top). A 600% increase in fluorescence was observed for the tested compounds, indicating that the 
dye had permeated the cellular membrane of the bacteria. As expected, both vancomycin and UltraPure H2O failed 
to give an increase in fluorescence. Interestingly, the fluorescence did not correlate with the MIC values, as the 
least potent monocationic derivative 39 gave the strongest fluorescence and the most potent compound 81 gave 
the weakest fluorescence. The dicationic derivatives (71 and 81) took much longer (~30 min) to reach a maximum 
fluorescence, relative to the monocationic derivative 39 (<10 min); these results indicate that the smaller, 
monocationic derivatives can permeabilize the cellular membrane more rapidly than the larger, dicationic 
derivatives. The monocationic compound 39 displayed a 75% increase in the observed fluorescence when tested 
against E. coli, similar to the positive control, colistin (Fig. 5, bottom), indicating successful permeabilization of 
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(25–40%), demonstrating a decreased propensity for permeabilization of Gram-negative cellular membranes 
relative to the monocationic analogue 39.  
 
 
Fig. 5. Cytoplasmic membrane permeabilization assays for compounds 39, 71 and 81 tested at 32 µg/mL against S. aureus 
(top) and E. coli (bottom). Vancomycin tested at 8 µg/mL and colistin tested at 64 µg/mL. 
3. Conclusion 
In total, forty-three cationic biaryl 1,2,3-triazolyl amphiphilic peptidomimetics were designed and 
prepared for antibacterial evaluation, including twenty-six monocationic amide analogues (A), seven dicationic 
amide analogues (B) and ten dicationic bis-triazole analogues (C). In vitro antibacterial susceptibility assays 
revealed that the synthesized 1,2,3-triazolyl amphiphiles maintained significant antimicrobial efficacy relative to 
the prototypical lead compound 1. The dicationic bis-triazole derivatives (Series C) were found to exhibit potent 
antibacterial activity, with compound 81 displaying MIC values of 2–4 µg/mL against all Gram-positive bacteria 
tested and 4–16 µg/mL against all Gram-negative bacteria tested. Compound 81 also showed increased Gram-
negative efficacy, relative to the monocationic and dicationic amide analogues (Series A and B, respectively) 
which displayed reduced or no antibacterial activity against the tested Gram-negative pathogens. Furthermore, the 
synthesized peptidomimetics were shown to exhibit excellent in vitro activity against multiple drug resistant 
Gram-positive strains, including MRSA, VRSA, VRE and S. aureus with reduced susceptibility to daptomycin.  
The ratio of cationic/hydrophobic moieties within the peptidomimetic amphiphiles was found to have a strong 
influence on their antimicrobial activity, haemolytic activity and membrane selectivity. The dicationic biphenyl 
bis-triazole derivatives (e.g. compound 81) were found to exhibit strong Gram-negative activity, but the 
corresponding (S)-binaphthyl analogues and monocationic derivatives were lacking sufficient activity against 
Gram-negative bacteria, likely due to steric bulk and/or a suboptimal amphiphilic conformation. The 
monocationic derivatives (Series A) were notably haemolytic due to a non-optimized amphiphilic structure; the 
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due to the cationic/hydrophobic ratio, thus resulting in increased antimicrobial activity and reduced haemolytic 
activity relative to the monocationic derivatives. Further optimization of the haemolytic activity and membrane 
selectivity will be necessary before this class of compounds can be considered for systemic application.  
Cytoplasmic membrane depolarization and permeabilization assays provided evidence of a membrane-active 
mechanism; compounds 39, 71 and 81 were found to strongly disrupt the membrane potential and permeabilize 
the cellular membrane of both S. aureus and E. coli. A time-kill kinetics assay further confirmed the likely mode 
of action, as compound 71 exhibited extremely rapid antibacterial efficacy, killing S. aureus within 30 min and E. 
coli within 2 h; these rapid bactericidal kinetics are similar to those of other membrane-active molecules (e.g. 
colistin).  
These preliminary investigations have revealed a likely mode of action for the 1,2,3-triazolyl 
biarylpeptidomimetics and they have provided further insight into the structural elements influencing the 
antimicrobial efficacy and haemolytic activity of the synthesized peptidomimetics.  
 
4. Experimental section 
4.1. General information 
Synthesis 
Unless stated otherwise, all solvents and chemicals were laboratory or reagent grade and were purchased 
from commercial sources. All chemicals were used as received. Water was purified via Millipore filtration prior 
to use. HOBt and propargyl bromide were purchased with added stabilizers (10% w/w H2O and 20% w/w toluene, 
respectively); therefore, the quantities required for reactions were adjusted accordingly and are reflected in the 
reagent masses reported in the experimental (whereas the reported mmol quantities reflect the true quantity of 
chemical). All reactions were conducted under normal atmosphere and cold reaction temperatures were obtained 
by an ice bath (0 ºC) or ice/salt bath (–10 ºC). Heating of reactions was performed with a paraffin oil bath. Small 
quantities of liquid reagents were measured and added to reactions via syringe or autopipette. Unless otherwise 
noted, all filtrations were conducted as vacuum filtration through a sintered glass funnel (medium porosity). 
Vacuum filtration was achieved with the aid of a water aspirator. Solvent removal via concentration was 
performed on a rotary evaporator under reduced pressure. All solvent mixtures are expressed in terms of volume 
ratio (i.e. v/v). Thin layer chromatography (TLC) was performed on aluminium-backed SiO2 gel plates (F254 grade 
- 0.20 mm thickness). Visualization was achieved with UV light, ninhydrin stain or cerium ammonium molybdate 
stain. Flash chromatography was performed on SiO2 gel 60 with positive air pressure. All synthesized compounds 
were dried under high vacuum (<1 mbar) before determination of chemical yields and spectroscopic 
characterization. 
Characterization and analysis 
1H NMR spectra were recorded on a Bruker Avance 400 (400 MHz), a Varian VNMRS PS54 500 (500 
MHz), a Varian Inova 500 (500 MHz) or a Varian Mercury 300 (300 MHz) NMR spectrometer. Chemical shifts 
are reported in ppm and were measured relative to the internal standard. Samples were dissolved in CDCl3 (with 
TMS as the internal standard – 0.00 ppm), CD3OD (solvent resonance as internal standard – 3.31 ppm) or DMSO-
d6 (solvent resonance as internal standard – 2.50 ppm). The 1H NMR data is reported as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, dt = doublet of triplets, m = multiplet, br = broad), 
coupling constants (Hz) and integration. 13C NMR spectra were recorded on a Bruker Avance 400 (101 MHz), a 
Varian VNMRS PS54 500 (126 MHz), a Varian Inova 500 (126 MHz) or a Varian Mercury 300 (75 MHz) NMR 
spectrometer with complete 1H decoupling. Chemical shifts are reported in ppm and were measured relative to 
the internal standard. Samples were dissolved in CDCl3 (solvent resonance as the internal standard – 77.16 ppm), 
CD3OD (solvent resonance as the internal standard – 49.20 ppm) or DMSO-d6 (solvent resonance as internal 
standard – 39.50 ppm). Variable temperature NMR experiments were performed at 90 C on the Bruker Avance 
400 NMR spectrometer. 1H and 13C NMR assignments were confirmed by analysis of NMR APT, gCOSY, 
gHSQC, gHMBC and/or zTOCSY experiments. Ambiguous degenerate carbon resonances are marked with a 
single asterisk * (representing two carbons) or a double asterisk ** (representing three or more carbons) for clarity. 
Carbon resonances that required 2-D NMR analysis for assignment (i.e. not observed via 1-D 13C NMR analysis) 
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are marked with the label “observed by gHMBC” or “observed by gHSQC”. NMR spectra were processed, 
analysed and prepared with MestReNova (version 6.0) NMR software. Low-resolution mass spectra (LRMS) 
were obtained via electrospray ionization (ESI) on a Shimadzu LC-2010 mass spectrometer. LRMS data was 
recorded as the ion mass/charge ratio (m/z) with the corresponding relative abundance as a percentage. High-
resolution mass spectrometry (HRMS) was performed on a Waters Quadrupole-Time of Flight (QTOF) Xevo 
spectrometer via ESI and with Leucine-Enkephalin as an internal standard. All mass spectrometry samples were 
dissolved in high-performance liquid chromatography (HPLC) grade MeOH (containing <1% formic acid for 
ionization). Optical rotations were measured on a Jasco P-2000 polarimeter with a 10 cm path length; rotation 
values (α) are expressed in units of “deg cm3 g-1 dm-1” with concentration (c) expressed in units of “g/100 mL”. 
Solid-state infrared spectroscopy was performed on a Shimadzu IRAffinity-1 FTIR spectrometer in combination 
with a MIRacle 10 Single Reflection Attenuated Total Reflectance accessory outfitted with a 1.5 mm round 
diamond crystal. IR peaks are reported as the wavenumber (ν̄max in cm-1) of the maximum absorption. Analytical 
HPLC was performed on a Phenomenex Synergi 4u Fusion-Reverse Phase 80Å column (φ = 4.6 × 150 mm) with 
detection at λ = 215 nm and H2O/CH3CN (both containing 0.1% TFA) as the mobile phase.  
Notes and other considerations 
Known reagents that were not available commercially were prepared according to the literature 
procedures cited within the supplementary information. The experimental section contains a representative 
synthesis of final compound 81 utilizing the general synthetic procedures outlined in Section 4.2; the synthetic 
and characterization data for all other compounds can be found within the supplementary information. Synthesized 
compounds that contain the (S)-isopentyloxy-binaphthalene fragment and some chiral compounds that contain the 
isopentyloxybiphenyl fragment exhibited a pair of diastereotopic methyl (-CH3) groups on the terminus of the 
isopentyl substituent; these carbons are consistently referred to as C4 and C5. Importantly, these two carbons 
(and associated protons) would sometimes exhibit distinct chemical shifts due to the chiral environment imposed 
by the amino acid residue(s) (for all derivatives) and/or the adjacent (S)-binaphthyl moiety (for (S)-binaphthyl 
derivatives only). 
 
4.2. General synthetic procedures 
 
General Procedure A: Copper catalyzed azide-alkyne cycloaddition  
To a reaction vessel charged with the azide (1.0 eq), alkyne (2.0 – 3.0 eq), Cu(OAc)2∙H2O (0.2 eq), and sodium 
ascorbate (0.4 eq) was added t-BuOH (20 mL/mmol azide) and H2O (5 mL/mmol azide). The mixture was initially 
sonicated for < 1 min followed by vigorous stirring at rt (unless noted otherwise) for the specified time. The 
reaction mixture was diluted with EtOAc (20 mL for reactions that contained ≤ 1.0 mmol azide or 20 mL/mmol 
azide for larger scale reactions) and washed with an equivalent volume of saturated aqueous NH4Cl solution (e.g. 
20 mL). The organic phase was dried (MgSO4), filtered, concentrated and the residue was subjected to flash 
chromatography over SiO2 gel to afford the desired 1,4-disubstituted-1,2,3-triazole product.  
General Procedure B: Amide coupling 
The amine (1.0 eq), carboxylic acid (1.0 – 1.2 eq), EDCI (1.2 eq) and HOBt (1.1 eq) were combined in an 
acetonitrile solution (10 mL/mmol amine) and stirred at rt for the specified time. The solvent was removed (not 
required for ≤ 5.0 mL acetonitrile) and the residue was dissolved in EtOAc (25 mL for reactions that contained ≤ 
1.0 mmol amine or 25 mL/mmol amine for larger scale reactions). The organic solution was washed successively 
with aqueous HCl (1.0 M – 2 × 25 mL), saturated aqueous NaHCO3 (3 × 25 mL) and brine (1 × 25 mL). The 
EtOAc solution was dried (MgSO4), filtered and concentrated. If necessary, the residue was subjected to further 
purification via flash chromatography over SiO2 gel to furnish the targeted amide product. 
General Procedure C: Amine deprotection (N-Boc and/or N-Pbf removal) 
The N-protected amine (1.0 eq) was dissolved in a CH2Cl2 (30 mL/mmol substrate) with magnetic stirring. If the 
substrate molecule contained an N-Pbf moiety then H2O (20.0 eq) was also added to the solution. TFA (30.0 
mL/mmol substrate) was then added and the reaction mixture was stirred at rt overnight (> 16 h) followed by 
removal of the solvent. The residue was dissolved in CH2Cl2 (30 mL/mmol substrate), an excess amount of 
anhydrous HCl (2.0 M in Et2O, 15 mL/mmol substrate, 30.0 eq) was added and the solvent was then removed. 
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The resulting residue was dissolved in a minimal volume of CH2Cl2 (or MeOH) and excess Et2O (25 mL for ≤ 0.1 
mmol substrate) was added to precipitate the hydrochloride salt of the amine. The solvent was removed by 
filtration and the product (both in the filter funnel and in the flask) was triturated with Et2O (3 × 20 mL). The 
product was collected by dissolution in MeOH; concentration followed by drying in vacuo gave the final mono- 
or di-hydrochloride salt as a thin, translucent film that was routinely scratched with a spatula into a fine 
hygroscopic powder or amorphous gum.  
General Procedure D: Modified amine deprotection (N-Boc removal) 
For the biphenyl monocationic lysine derivatives (38–40), General Procedure C was followed with the following 
modifications: Et2O (instead of CH2Cl2 or MeOH) was utilized to dissolve the residue for final precipitation and 
petroleum ether (P.E. – instead of Et2O) was utilized as the antisolvent for precipitation.  
4.3. Representative synthesis of compound 81 from precursor building blocks 15 and 21 
4.3.1. Benzyl ((R)-N6-(tert-butoxycarbonyl)-6-amino-1-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-
1H-1,2,3-triazol-1-yl)hexan-2-yl)carbamate (29) 
Following General Procedure A, azide 21 (1.50 g, 3.83 mmol), alkyne 15 (2.26 g, 7.66 mmol), 
Cu(OAc)2∙H2O (153 mg, 0.77 mmol) and sodium ascorbate (304 mg, 1.53 mmol) were stirred in t-BuOH (77 mL) 
and H2O (19 mL) for 48 h to give the triazole 29 (1.97 g, 75%) as a white foam after flash chromatography over 




 +31.3 (c 0.83, MeOH); 1H 
NMR (400 MHz, CDCl3) δ 7.38 – 7.21 (m, 9H), 7.17 (s, 1H), 7.07 – 6.99 (m, 2H), 6.99 – 6.91 (m, 2H), 5.14 (s, 
2H), 5.06 (s, 3H), 4.55 (br s, 1H), 4.39 (d, J = 5.1 Hz, 2H), 3.92 (br s, 1H), 3.88 (t, J = 6.6 Hz, 2H), 3.06 (br s, 
2H), 1.62 – 1.52 (m, 1H), 1.52 – 1.23 (m, 17H), 0.79 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 156.6, 
156.2, 155.9, 155.8, 145.2, 136.2, 131.7, 131.5, 128.7, 128.54*, 128.46, 128.2, 128.1*, 123.3, 121.1, 120.1, 113.3, 
112.3, 79.2, 67.0, 66.9, 63.4, 53.1, 51.2, 39.8, 37.9, 31.0, 29.7, 28.4, 25.0, 22.7, 22.5*; IR (neat) ν̄max 3323, 2952, 
2930, 2869, 2358, 2342, 1696, 1506, 1437, 1394, 1364, 1242, 1166, 1052, 1011, 856, 750, 697 cm-1; MS (ESI 
+ve) m/z 708 ([M + Na]+, 100%), 686 ([M + H]+, 22%); HRMS (ESI +ve TOF) calcd for C39H51N5O6Na 708.3737, 




To a reaction vessel charged with carbamate 29 (1.90 g, 2.77 mmol), acetic acid (3.17 mL, 55.40 mmol) 
and palladium on charcoal (10% w/w – 442 mg, 0.42 mmol) was added MeOH (27.7 mL) under a flow of N2 gas. 
The reaction vessel was then sealed and degassed under high vacuum with magnetic stirring. N2 gas was allowed 
into the reaction vessel and the vessel was again degassed; this step was done twice. After the third degassing, the 
vacuum was maintained and a 2.0 L balloon of H2 gas was attached and allowed into the reaction vessel. The 
reaction mixture was then stirred vigorously at rt for 24 h under an atmosphere of H2 gas. After the reaction was 
shown to be complete by TLC analysis (EtOAc/P.E. – 50:50), the H2 source was removed, the reaction vessel was 
purged with N2 gas and Celite was added to the reaction mixture with vigorous magnetic stirring. The mixture 
was then vacuum filtered through a pad of fresh Celite atop a PTFE membrane, the solids were rinsed thoroughly 
with MeOH (5 × 20 mL) and the combined filtrates were concentrated until nearly dry. The residue was dissolved 
in CH2Cl2 (200 mL) and washed successively with saturated aqueous NaHCO3 (3 × 100 mL), H2O (1 × 100 mL) 
and finally brine (1 × 100 mL). The organic phase was dried (Na2SO4), filtered and concentrated to afford the 





(c 1.67, MeOH); 1H NMR (400 MHz, CDCl3) δ 7.34 – 7.22 (m, 5H), 7.08 – 6.92 (m, 4H), 5.17 (d, J = 0.8 Hz, 
2H), 4.57 (br s, 1H), 4.28 (dd, J = 13.6, 4.2 Hz, 1H), 4.07 (dd, J = 13.6, 7.9 Hz, 1H), 3.90 (t, J = 6.6 Hz, 2H), 3.21 
– 3.02 (m, 3H), 1.68 – 1.21 (m, 18H), 0.80 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 156.6, 156.0, 
155.8, 145.2, 131.62, 131.56, 128.7, 128.50, 128.49, 128.2, 123.1, 121.1, 120.1, 113.2, 112.3, 79.2, 67.1, 63.54, 
57.0, 51.5, 40.2, 38.0, 34.5, 30.0, 28.5, 25.0, 23.0, 22.5*; IR (neat) ν̄max 3345, 2955, 2930, 2869, 2362, 2327, 1700, 
1506, 1437, 1388, 1364, 1241, 1166, 1125, 1051, 1002, 852, 750, 615 cm-1; MS (ESI +ve) m/z 574 ([M + Na]+, 







Following General Procedure B, amine 34 (300 mg, 0.54 mmol), acid 26 (271 mg, 0.60 mmol), EDCI 
(125 mg, 0.65 mmol) and HOBt (88 mg, 0.60 mmol) were stirred in acetonitrile (5.4 mL) for 48 h to give the 
amide 75 (479 mg, 89%) as a translucent tan gum after flash chromatography over SiO2 gel (EtOAc/P.E. – 30:70 
→ 80:20). TLC (EtOAc/P.E. – 80:20): Rf  = 0.53; [α]
2
D
 3 −14.7 (c 2.97, MeOH); 1H NMR (400 MHz, CDCl3) δ 7.48 
(br s, 2H), 7.33 – 7.19 (m, 4H), 7.09 (d, J = 8.0 Hz, 1H), 7.05 – 6.92 (m, 3H), 6.26 (br s, 2H), 5.90 (br s, 1H), 5.11 
(s, 2H), 4.70 (br s, 1H), 4.49 – 4.32 (m, 3H), 3.97 – 3.82 (m, 3H), 3.35 (br s, 1H), 3.06 (br s, 2H), 2.95 (s, 2H), 
2.89 (br s, 1H), 2.58 (s, 3H), 2.51 (s, 3H), 2.09 (s, 3H), 1.63 – 1.19 (m, 28H), 0.80 (d, J = 6.5 Hz, 6H); 13C NMR 
(101 MHz, CDCl3) δ 170.9, 159.0, 156.5, 156.4, 156.3, 156.1, 144.6, 138.4, 132.7, 132.3, 131.9, 131.8, 128.9, 
128.4, 128.0, 124.8, 124.0, 121.5, 120.5, 117.7, 114.2, 112.8, 86.6, 79.2, 67.3, 63.7, 61.0, 53.7, 49.4, 43.4, 40.3, 
38.5, 38.0, 31.6, 29.6, 28.7, 28.5, 27.6, 25.6, 25.1, 23.1, 22.6, 22.5, 19.5, 18.1, 12.6; IR (neat) ν̄max 3455, 3335, 
2954, 2933, 2875, 2375, 2331, 2104, 1689, 1653, 1559, 1540, 1512, 1457, 1437, 1368, 1243, 1162, 1107, 1091, 
1053, 1031, 1003, 903, 853, 807, 784, 751, 734, 663, 641, 617 cm-1; MS (ESI +ve) m/z 1009 ([M + Na]+, 100%), 
987 ([M + H]+, 17%); HRMS (ESI +ve TOF) calcd for C50H72N11O8S 986.5286, found 986.5305 ([M + H]+). 
 
4.3.4. (R)-N-((R)-6-Amino-1-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-1,2,3-triazol-1-
yl)hexan-2-yl)-5-guanidino-2-(4-(cyclohexylmethyl)-1H-1,2,3-triazol-1-yl)pentanamide dihydrochloride (81) 
Following General Procedure A, azide 75 (50 mg, 0.05 mmol), 3-cyclohexyl-1-propyne (19 mg, 0.15 
mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol) were stirred in t-BuOH (1.0 
mL) and H2O (0.25 mL) for 20 h to give the intermediate triazole as a light tan gum after flash chromatography 
over SiO2 gel (MeOH/CH2Cl2. – 0:100 → 10:90). Following General Procedure C, the triazole was dissolved in 
CH2Cl2 (1.5 mL) and treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with 
ethereal HCl to give the amine salt 81 (33 mg, 79% over two steps) as a light tan powder that rapidly transitioned 




 −23.4 (c 0.80, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.93 (s, 1H), 7.84 (s, 1H), 7.36 – 
7.24 (m, 2H), 7.23 – 7.13 (m, 3H), 7.06 – 6.91 (m, 3H), 5.34 – 5.26 (m, 1H), 5.13 (s, 2H), 4.59 (dd, J = 13.9, 3.8 
Hz, 1H), 4.44 (dd, J = 13.9, 8.9 Hz, 1H), 4.27 (br s, 1H), 3.92 (t, J = 6.2 Hz, 2H), 3.10 (t, J = 6.8 Hz, 2H), 2.89 (t, 
J = 7.1 Hz, 2H), 2.61 (d, J = 6.8 Hz, 2H), 2.11 – 1.89 (m, 2H), 1.77 – 1.13 (m, 20H), 1.04 – 0.91 (m, 2H), 0.81 
(d, J = 6.2 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 169.7, 158.7, 158.2, 157.5, 147.3 (observed by gHMBC), 
145.8 (observed by gHMBC), 133.1, 132.7, 130.5, 129.9, 129.82, 129.76, 126.2, 124.8, 122.5, 121.5, 115.0, 113.9, 
68.3, 65.2, 63.7, 54.7, 51.4, 41.7, 40.7, 39.44, 39.41, 34.2*, 33.7, 32.3, 30.4, 28.2, 27.6, 27.4*, 26.3, 26.1, 23.9, 
23.1*; IR (neat) ν̄max 3158, 3065, 2950, 2926, 2869, 2380, 2350, 2312, 1734, 1718, 1700, 1684, 1653, 1636, 1559, 
1540, 1521, 1507, 1473, 1457, 1437, 1419, 1363, 1340, 1260, 1213, 1161, 1125, 1109, 1040, 1003, 855, 750, 735, 
701, 669, 608 cm-1; MS (ESI +ve) m/2 379 ([M + 2H]2+, 100%), m/z 756 ([M + H]+, 19%), 778 ([M + Na]+, 16%); 
HRMS (ESI +ve TOF) calcd for C41H62N11O3 756.5037, found 756.5072 ([M + H]+). 
 
4.4. Microbiology assays 
 
4.4.1. Primary screening (Gram-positive bacteria)  
Primary MIC assays were performed as described by the Clinical and Laboratory Standards Institute for 
aerobic [36] and anaerobic [37] bacteria. S. aureus strains ATCC 29213 and NCTC 10442 (MRSA) and E. faecalis 
(ATCC 29212) were tested in Mueller Hinton broth (MHB) and incubation was performed in ambient air at 35 °C 
for 24 h. S. pneumoniae (ATCC 49619) was cultivated in MHB with 2.5% lysed horse blood and incubated with 
5% CO2 at 35 °C for 24 h. MIC studies for C. difficile strains ATCC 700057 and NSW132 (RT027) were 
conducted in pre-reduced (2-4 h) Brucella broth supplemented with haemin and vitamin K and incubation was 
performed anaerobically at 35 °C in a Don Whitley Scientific anaerobic chamber (A35) for 48 h. Each compound 
was dissolved in DMSO at 5 mg/mL and then diluted to 512 μg/mL with sterile, distilled water. The compounds 
were then serially diluted in 100 μL volumes of sterile, distilled water in a 96-well microtitre tray. Each test 
organism in double strength broth (100 μL) was then added to each well and incubated as described above. Final 
testing concentrations of the compounds ranged from 0.25 μg/mL to 128 μg/mL. Vancomycin and a control well 
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(i.e. no antibacterial compound present) were included in the assays. A DMSO control (5% v/v) was also tested 
to ensure that the solvent did not inhibit bacterial growth. The assay was performed in triplicate for each 
organism/compound combination and the modal MIC values were recorded. The MIC was determined visually 
as the lowest concentration that inhibited bacterial growth. Concentrations of ≤5% DMSO were not inhibitory to 
growth. MIC values for vancomycin were within acceptable QC ranges [38]. 
 
4.4.2. Secondary screening (MRSA and Gram-negative bacteria) and cytotoxicity assay – performed by the 
Community for Open Antimicrobial Drug Discovery (CO-ADD) 
 Samples were provided to CO-ADD [34] for antimicrobial screening by whole cell growth inhibition 
assays. The inhibition of growth was measured against five bacteria: E. coli (ATCC 25922), K. pneumoniae 
(ATCC 700603), A. baumannii (ATCC 19606), P. aeruginosa (ATCC 27853) and S. aureus (ATCC 43300). In 
addition to the MIC assay, compounds were screened for cytotoxicity against a human embryonic kidney cell line 
(HEK293) by determining their CC50 value. Samples were prepared in DMSO to a final testing concentration of 
32 μg/mL and serially diluted 1:2 fold for 8 times. Each sample concentration was prepared in 384-well plates; 
non-binding surface (NBS) plates (Corning 3640) for each bacterial strain and black plates (Corning 3712/3764) 
for mammalian cell types, all in duplicate (n = 2) and keeping the final DMSO concentration to a maximum of 
0.5%. All the sample preparation was done using liquid handling robots.  
Bacterial Inhibition – MIC Assay 
All bacteria were cultured in Cation-adjusted MHB at 37 °C overnight. A sample of each culture was then diluted 
40-fold in fresh broth and incubated at 37 °C for 1 – 3.5 h. The resultant mid-log phase cultures were diluted 
(CFU/mL measured by OD600), then added to each well of the compound-containing plates, giving a cell density 
of 5 × 105 CFU/mL and a total volume of 50 μL. All plates were covered and incubated at 37 °C for 18 h without 
shaking. Inhibition of bacterial growth was determined by measuring absorbance at 600 nm (OD600), using a Tecan 
M1000 Pro monochromator plate reader. The percentage of growth inhibition was calculated for each well, using 
the negative control (media only) and positive control (bacteria without inhibitors) on the same plate as references. 
The MIC was determined as the lowest concentration at which growth was fully inhibited, defined by an inhibition 
≥80%. Colistin and vancomycin were used as positive bacterial inhibitor standards for Gram-negative and Gram-
positive bacteria, respectively. Each antibiotic standard was provided in four concentrations, with two above and 
two below its MIC value, and plated into the first eight wells of column 23 of the 384-well NBS plates. 
Cytotoxicity Assay 
HEK293 cells were counted manually in a Neubauer haemocytometer and then plated in the 384-well plates 
containing the compounds to give a density of 5000 cells/well in a final volume of 50 μL. Dulbecco’s modified 
eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) was used as a growth media and the 
cells were incubated together with the compounds for 20 h at 37 °C in 5% CO2. Cytotoxicity (cell viability) was 
measured by fluorescence (ex: 560/10 nm, em: 590/10 nm), after addition of 5 μL of 25 μg/mL resazurin (2.3 
μg/mL final concentration) and after incubation for further 3 h at 37 °C in 5% CO2. The fluorescence intensity 
was measured using a Tecan M1000 Pro monochromator plate reader, using automatic gain calculation. CC50 
(concentration at 50% cytotoxicity) values were calculated by curve-fitting the inhibition values vs. 
log(concentration) using a sigmoidal dose-response function, with variable fitting values for bottom, top and 
slope. Tamoxifen was utilized as a positive cytotoxicity standard; it was used in eight concentrations in two-fold 
serial dilutions with 50 μg/mL as the highest concentration tested. 
 
 
4.4.3. Extended panel screening (drug resistant Gram-positive bacteria) – performed by the Community for Open 
Antimicrobial Drug Discovery (CO-ADD) 
 Extended panel MIC assays were performed by CO-ADD as per section 4.4.2 against the following 
bacterial strains: S. aureus ATCC 43300 (MRSA), S. aureus clinical isolate (MRSA), S. aureus NRS17 (GISA), 
S. aureus NRS1 (GISA/MRSA), S. aureus clinical isolate (MRSA/reduced daptomycin susceptibility), S. aureus 
VRS10 – NARSA (VRSA), S. pneumoniae ATCC700677 (MDR), and E. faecalis clinical isolate (VRE). 




4.4.4. Haemolysis assay 
The haemolytic activity of the synthesized compounds was determined by lysis of sheep erythrocytes. 
Briefly, 500 μL volumes of each compound in phosphate buffer solution (PBS) were mixed with 480 μL PBS and 
20 μL washed sheep erythrocytes (100%) in microcentrifuge tubes; this produced a final erythrocyte concentration 
of 2%. Compounds were tested at both 5 μg/mL and 50 μg/mL. A positive control (980 μL water and 20 μL 
erythrocytes) and a negative control (980 μL PBS and 20 μL erythrocytes) were also included in the assay. The 
centrifuge tubes were incubated on a rocker at 37 °C for 2 h and then centrifuged at 12,000 rpm for 5 min; 100 
µL volumes of the supernatant fluid were transferred to a 96-well microtitre tray and the optical density of the 
samples was observed at 540 nm. The value for the negative control was subtracted from the haemolysis values 
and then the resulting quantities were expressed as a percentage of the positive control (which was defined as 
100% haemolysis). The haemolysis assay was repeated in triplicate for all compounds and the mean values were 
reported. 
 
4.4.5. Time-kill kinetics assay 
A 100 µl aliquot of a 0.5 McFarland standard of S. aureus ATCC 29213 or E. coli ATCC 25922 was 
inoculated in 20 mL of MHB and incubated at 37 °C for 18 h ('overnight culture'). The overnight culture was 
diluted 1 in 1,000 in MHB. For each organism, three 5 mL aliquots were prepared in 10 mL tubes. The tubes 
were incubated at 37 °C, lid loose, with aeration (225 rpm) for 2 h (early exponential phase). The bacterial cultures 
were then challenged with compound 71 at 64 µg/mL (8–16 × MIC) and incubation was continued at 37 °C, lid 
loose, with aeration (225 rpm). A 100 µL aliquot was taken from each tube before the challenge (T=0), 30 min 
after challenge, 60 min after the challenge and then at 1 h intervals until total time = 6 h. Ten-fold serially diluted 
suspensions of each 100 µL aliquot were plated onto pre-dried blood agar plates. The blood agar plates were 
incubated for 18 h at 37 °C. Colonies were counted and CFU/mL were calculated. UltraPure H2O was utilized as 
a negative control for both species. Vancomycin (8 µg/mL) was used as an antibiotic control for S. aureus and 
colistin (4 µg/mL) was used as an antibiotic control for E. coli. The limit of detection = 103 CFU/mL. 
 
4.4.6. Cytoplasmic membrane depolarization assay 
An inoculum containing 1.5 McFarland standard of mid-log cells (S. aureus ATCC 29213 or E. coli 
NCTC 10418) was suspended in either phosphate buffered saline (PBS – for S. aureus) or a 5 mM HEPES solution 
containing 20 mM glucose adjusted to pH 7.2 (for E. coli). Then, 3,3ʹ-dipropylthiadicarbocyanine (diSC3(5)) was 
added at 4 µM to the bacteria suspension and the mixture was incubated in the dark at room temperature (30 min 
for S. aureus and 60 min for E. coli). For E. coli only, KCl was then added at 100 mM, followed by EDTA at 
0.5 mM. Then, 100 µL aliquots of the bacterial suspension were added to wells of a 96-well plate (black with 
clear bottom); the fluorescence was tracked (ex: 620/10 nm, em: 670/10 nm) for approximately 8 min prior to 
exposure to the test compounds. The content of each well was then transferred to a different well containing 
100 µL of one of the various test compounds prepared at double the final test concentration. The fluorescence was 
then tracked for approximately 30 min. The final assay concentration of the test compounds was 32 µg/mL for S. 
aureus and 64 µg/mL for E. coli. UltraPure H2O was utilized as a negative control for both species. DMSO (20%) 
was utilized as a positive control for both species. Vancomycin (8 µg/mL) was used as a negative control for S. 
aureus and colistin (64 µg/mL) was used as positive control for E. coli. 
4.4.7. Cytoplasmic membrane permeabilization assay 
An inoculum containing 1.5 McFarland standard of mid-log cells (S. aureus ATCC 29213 or E. coli 
NCTC 10418) was suspended in either phosphate buffered saline (PBS – for S. aureus) or a 5 mM HEPES solution 
containing 20 mM glucose adjusted to pH 7.2 (for E. coli). Then, propidium iodide was added at 4 µM to the 
bacteria suspension and the mixture was incubated in the dark at room temperature (30 min for S. aureus and 60 
min for E. coli). For E. coli only, KCl was then added at 100 mM, followed by EDTA at 0.5 mM. Then, 100 µL 
aliquots of the bacterial suspension were added to wells of a 96-well plate (black with clear bottom); the 
fluorescence was tracked (ex: 544/10 nm, em: 615/10 nm) for approximately 8 min prior to exposure to the test 
compounds. The content of each well was then transferred to a different well containing 100 µL of one of the 
various test compounds prepared at double the final test concentration. The fluorescence was then tracked for 
approximately 30 min. The final assay concentration of the test compounds was 32 µg/mL for both S. aureus and 
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E. coli. UltraPure H2O was utilized as a negative control for both species. Vancomycin (8 µg/mL) was used as a 
negative control for S. aureus and colistin (64 µg/mL) was used as a positive control for E. coli. 
Acknowledgements 
 The authors thank the Australian National Health and Medical Research Council (NHMRC) for financial 
support (Grant #APP1124032). The authors are grateful for antimicrobial screening that was performed by CO-
ADD (The Community for Antimicrobial Drug Discovery), funded by the Wellcome Trust (UK) and The 
University of Queensland (Australia). 
Declarations of Interest 
 The authors declare no competing financial interests. 
Appendix A. Supplementary information 






























1. World Health Organization. Antibiotic Resistance Fact Sheet. 
http://www.who.int/mediacentre/factsheets/antibiotic-resistance/en/ (accessed June 12th, 2018). 
2. Centers for Disease Control. Antibiotic/Antimicrobial Resistance. 
https://www.cdc.gov/drugresistance/ (accessed June 12th, 2018) 
3. Roca, I.; Akova, M.; Baquero, F.; Carlet, J.; Cavaleri, M.; Coenen, S.; Cohen, J.; Findlay, D.; Gyssens, 
I.; Heure, O. E.; et al. The global threat of antimicrobial resistance: science for intervention. New 
Microbes New Infect. 2015, 6, 22-9. 
4. Pourmand, A.; Mazer-Amirshahi, M.; Jasani, G.; May, L. Emerging trends in antibiotic resistance: 
Implications for emergency medicine. Am. J. Emerg. Med. 2017, 35 (8), 1172-1176. 
5. Martens, E.; Demain, A. L. The antibiotic resistance crisis, with a focus on the United States. J. Antibiot. 
2017, 70 (5), 520-526. 
6. Pendleton, J. N.; Gorman, S. P.; Gilmore, B. F. Clinical relevance of the ESKAPE pathogens. Expert 
Review of Anti-infective Therapy 2013, 11 (3), 297-308. 
7. Penchovsky, R.; Traykovska, M. Designing drugs that overcome antibacterial resistance: where do we 
stand and what should we do? Expert. Opin. Drug Discov. 2015, 10 (6), 631-650. 
8. Ghosh, C.; Haldar, J. Membrane-Active Small Molecules: Designs Inspired by Antimicrobial Peptides. 
ChemMedChem 2015, 10 (10), 1606-1624. 
9. Herzog, I. M.; Fridman, M. Design and synthesis of membrane-targeting antibiotics: from peptides- to 
aminosugar-based antimicrobial cationic amphiphiles. MedChemComm 2014, 5 (8), 1014-1026. 
10. Molchanova, N.; Hansen, P. R.; Franzyk, H. Advances in Development of Antimicrobial 
Peptidomimetics as Potential Drugs. Molecules (Basel, Switzerland) 2017, 22 (9), 1430. 
11. Hein-Kristensen, L.; Franzyk, H.; Holch, A.; Gram, L. Adaptive Evolution of Escherichia coli to an α-
Peptide/β-Peptoid Peptidomimetic Induces Stable Resistance. PLOS ONE 2013, 8 (9), e73620. 
12. Ghosh, C.; Manjunath, G. B.; Akkapeddi, P.; Yarlagadda, V.; Hoque, J.; Uppu, D.; Konai, M. M.; 
Haldar, J. Small Molecular Antibacterial Peptoid Mimics: The Simpler the Better! Journal of Medicinal 
Chemistry 2014, 57 (4), 1428-1436. 
13. Kuppusamy, R.; Yasir, M.; Berry, T.; Cranfield, C. G.; Nizalapur, S.; Yee, E.; Kimyon, O.; Taunk, A.; 
Ho, K. K. K.; Cornell, B.; Manefield, M.; Willcox, M.; Black, D. S.; Kumar, N. Design and synthesis 
of short amphiphilic cationic peptidomimetics based on biphenyl backbone as antibacterial agents. 
European Journal of Medicinal Chemistry 2018, 143, 1702-1722. 
14. Wales, S. M.; Hammer, K. A.; King, A. M.; Tague, A. J.; Lyras, D.; Riley, T. V.; Keller, P. A.; Pyne, 
S. G. Binaphthyl-1,2,3-triazole peptidomimetics with activity against Clostridium difficile and other 
pathogenic bacteria. Org. Biomol. Chem. 2015, 13 (20), 5743-5756. 
15. Wales, S. M.; Hammer, K. A.; Somphol, K.; Kemker, I.; Schroder, D. C.; Tague, A. J.; Brkic, Z.; King, 
A. M.; Lyras, D.; Riley, T. V.; Bremner, J. B.; Keller, P. A.; Pyne, S. G., Synthesis and antimicrobial 
activity of binaphthyl-based, functionalized oxazole and thiazole peptidomimetics. Org. Biomol. Chem. 
2015, 13 (44), 10813-10824. 
16. Lin, S.; Koh, J.-J.; Aung, T. T.; Lim, F.; Li, J.; Zou, H.; Wang, L.; Lakshminarayanan, R.; Verma, C.; 
Liu, S.; et al. Symmetrically Substituted Xanthone Amphiphiles Combat Gram-Positive Bacterial 
Resistance with Enhanced Membrane Selectivity. J. Med. Chem. 2017, 60 (4), 1362-1378. 
17. Chu, W.-C.; Bai, P.-Y.; Yang, Z.-Q.; Cui, D.-Y.; Hua, Y.-G.; Yang, Y.; Yang, Q.-Q.; Zhang, E.; Qin, 
S. Synthesis and antibacterial evaluation of novel cationic chalcone derivatives possessing broad 
spectrum antibacterial activity. Eur. J. Med. Chem. 2018, 143, 905-921. 
30 
 
18. Zhang, E.; Bai, P.-Y.; Cui, D.-Y.; Chu, W.-C.; Hua, Y.-G.; Liu, Q.; Yin, H.-Y.; Zhang, Y.-J.; Qin, S.; 
Liu, H.-M. Synthesis and bioactivities study of new antibacterial peptide mimics: The dialkyl cationic 
amphiphiles. Eur. J. Med. Chem. 2018, 143, 1489-1509. 
19. Vooturi, S. K.; Dewal, M. B.; Firestine, S. M. Examination of a synthetic benzophenone membrane-
targeted antibiotic. Org. Biomol. Chem. 2011, 9 (18), 6367-6372. 
20. Ahn, M.; Gunasekaran, P.; Rajasekaran, G.; Kim, E. Y.; Lee, S.-J.; Bang, G.; Cho, K.; Hyun, J.-K.; 
Lee, H.-J.; Jeon, Y. H.; Kim, N.-H.; Ryu, E. K.; Shin, S. Y.; Bang, J. K. Pyrazole derived ultra-short 
antimicrobial peptidomimetics with potent anti-biofilm activity. Eur. J. Med. Chem. 2017, 125, 551-
564. 
21. Lai, X.-Z.; Feng, Y.; Pollard, J.; Chin, J. N.; Rybak, M. J.; Bucki, R.; Epand, R. F.; Epand, R. M.; 
Savage, P. B. Ceragenins: Cholic Acid-Based Mimics of Antimicrobial Peptides. Accounts Chem. Res. 
2008, 41 (10), 1233-1240. 
22. Nilsson, A. C.; Janson, H.; Wold, H.; Fugelli, A.; Andersson, K.; Håkangård, C.; Olsson, P.; Olsen, W. 
M. LTX-109 Is a Novel Agent for Nasal Decolonization of Methicillin-Resistant and -Sensitive 
Staphylococcus aureus. Antimicrob. Agents Chemother. 2015, 59 (1), 145-151. 
23. Isaksson, J.; Brandsdal, B. O.; Engqvist, M.; Flaten, G. E.; Svendsen, J. S. M.; Stensen, W. A Synthetic 
Antimicrobial Peptidomimetic (LTX 109): Stereochemical Impact on Membrane Disruption. J. Med. 
Chem. 2011, 54 (16), 5786-5795. 
24. Hoque, J.; Konai, M. M.; Sequeira, S. S.; Samaddar, S.; Haldar, J. Antibacterial and Antibiofilm 
Activity of Cationic Small Molecules with Spatial Positioning of Hydrophobicity: An in Vitro and in 
Vivo Evaluation. J. Med. Chem. 2016, 59 (23), 10750-10762. 
25. O'Neill, A. New antibacterial agents for treating infections caused by multi-drug resistant Gram-
negatve bacteria. Expert Opin. Investig. Drugs 2008, 17 (3), 297-302. 
26. Bremner, J. B.; Keller, P. A.; Pyne, S. G.; Boyle, T. P.; Brkic, Z.; David, D. M.; Garas, A.; Morgan, J.; 
Robertson, M.; Somphol, K.; et al. Binaphthyl-Based Dicationic Peptoids with Therapeutic Potential. 
Angew. Chem.-Int. Edit. 2010, 49 (3), 537-540. 
27. Bremner, J. B.; Keller, P. A.; Pyne, S. G.; Boyle, T. P.; Brkic, Z.; David, D. M.; Robertson, M.; 
Somphol, K.; Baylis, D.; Coates, J. A.; et al. Synthesis and antibacterial studies of binaphthyl-based 
tripeptoids. Part 1. Bioorg. Med. Chem. 2010, 18 (7), 2611-2620. 
28. Bremner, J. B.; Keller, P. A.; Pyne, S. G.; Boyle, T. P.; Brkic, Z.; Morgan, J.; Somphol, K.; Coates, J. 
A.; Deadman, J.; Rhodes, D. I. Synthesis and antibacterial studies of binaphthyl-based tripeptoids. Part 
2. Bioorg. Med. Chem. 2010, 18 (13), 4793-4800. 
29. Garas, A.; Bremner, J. B.; Coates, J.; Deadman, J.; Keller, P. A.; Pyne, S. G.; Rhodes, D. I. Binaphthyl 
scaffolded peptoids via ring-closing metathesis reactions and their anti-bacterial activities. Bioorg. 
Med. Chem. Lett. 2009, 19 (11), 3010-3013. 
30. Khara, J. S.; Priestman, M.; Uhía, I.; Hamilton, M. S.; Krishnan, N.; Wang, Y.; Yang, Y. Y.; Langford, 
P. R.; Newton, S. M.; Robertson, B. D.; Ee, P. L. R. Unnatural amino acid analogues of membrane-
active helical peptides with anti-mycobacterial activity and improved stability. J. Antimicrob. 
Chemother. 2016, 71 (8), 2181-2191. 
31. Boyle, T. P.; Bremner, J. B.; Brkic, Z.; Coates, J. A. V.; Dalton, N. K.; Deadman, J.; Keller, P. A.; 
Morgan, J.; Pyne, S. G.; Rhodes, D. I.; Robertson, M. J. Preparation of biaryl-based peptides for the 
treatment of infection. WO2006074501A1, 2006. 
32. Rodionov, V. O.; Fokin, V. V.; Finn, M. G. Mechanism of the ligand-free Cu-I-catalyzed azide-alkyne 
cycloaddition reaction. Angew. Chem.-Int. Edit. 2005, 44 (15), 2210-2215. 
31 
 
33. Rodionov, V. O.; Presolski, S. I.; Díaz Díaz, D.; Fokin, V. V.; Finn, M. G. Ligand-Accelerated Cu-
Catalyzed Azide−Alkyne Cycloaddition:  A Mechanistic Report. J. Am. Chem. Soc. 2007, 129 (42), 
12705-12712. 
34. Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. A stepwise Huisgen cycloaddition 
process: Copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew. Chem.-
Int. Edit. 2002, 41 (14), 2596. 
35. Blaskovich, M. A. T.; Zuegg, J.; Elliott, A. G.; Cooper, M. A. Helping Chemists Discover New 
Antibiotics. ACS Infect. Dis. 2015, 1 (7), 285-287. 
36.  Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests 
for Bacteria That Grow Aerobically; Approved Standard – Ninth Edition. 2015. CLSI Document M07-
A10. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania. 
37.  Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing of 
Anaerobic Bacteria; Approved Standard – Eighth Edition. 2012. CLSI Document M11-A8. Clinical 
and Laboratory Standards Institute, Wayne, Pennsylvania. 
38.  Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility 
Testing, 28th Informational Supplement. 2018. CLSI document M100-S28. Clinical and Laboratory 
Standards Institute, Wayne, Pennsylvania. 
 
